Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for John R. Hallal
-4.67 (-2.59%)
Real-time:   12:51PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 174.69 - 180.00
52 week 136.37 - 203.30
Open 180.00
Vol / Avg. 687,260.00/1.16M
Mkt cap 35.50B
P/E 53.89
Div/yield     -
EPS 3.26
Shares 202.15M
Beta 0.65
Inst. own 96%
May 4, 2015
Alexion Pharmaceuticals, Inc. Annual Shareholder Meeting (Estimated) Add to calendar
Apr 22, 2015
Q1 2015 Alexion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 12, 2015
Alexion Pharmaceuticals Inc at Barclays Healthcare Conference
Mar 2, 2015
Alexion Pharmaceuticals Inc at Cowen Health Care Conference
Feb 23, 2015
Alexion Pharmaceuticals Inc at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
Feb 12, 2015
Alexion Pharmaceuticals Inc at Leerink Global Healthcare Conference
Jan 29, 2015
Q4 2014 Alexion Pharmaceuticals Inc Earnings Call - Webcast
Jan 29, 2015
Q4 2014 Alexion Pharmaceuticals Inc Earnings Release
Jan 12, 2015
Alexion Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 25.58% 29.41%
Operating margin 33.98% 38.89%
EBITD margin - 43.10%
Return on average assets 15.20% 17.47%
Return on average equity 19.14% 23.11%
Employees 2,273 -
CDP Score - -


352 Knotter Dr
CHESHIRE, CT 06410-1138
United States - Map
+1-203-7761790 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alexion Pharmaceuticals, Inc. (Alexion), is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. The Company is also evaluating other indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism, and it is progressing with other biotechnology product candidates in ultra-rare and severe disorders, which are in various stages of development.

Officers and directors

Leonard Bell M.D. Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Vikas Sinha CPA Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
David L. Hallal Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
John B. Moriarty J.D. Executive Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 58
Bio & Compensation  - Reuters
Julie O'Neill Executive Vice President - Global Operations
Age: 48
Bio & Compensation  - Reuters
Dominique Monnet Senior Vice President, Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Edward Miller J.D. Senior Vice President, Global Chief Compliance Officer
Age: 50
Bio & Compensation  - Reuters
Saqib Islam J.D. Senior Vice President, Chief Strategy and Portfolio Officer
Age: 45
Bio & Compensation  - Reuters